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Anti-epidermal growth factor receptor conjugated
mesoporous zinc oxide nanoﬁbers for breast
cancer diagnostics†
Md. Azahar Ali,‡a Kunal Mondal,‡a Chandan Singh,b Bansi Dhar Malhotra*c and
Ashutosh Sharma*a
We report the fabrication of an eﬃcient, label-free, selective and highly reproducible immunosensor with
unprecedented sensitivity (femto-molar) to detect a breast cancer biomarker for early diagnostics. Meso-
porous zinc oxide nanoﬁbers (ZnOnFs) are synthesized by electrospinning technique with a ﬁber diameter
in the range of 50–150 nm. Fragments of ZnOnFs are electrophoretically deposited on an indium tin
oxide glass substrate and conjugated via covalent or electrostatic interactions with a biomarker (anti-
ErbB2; epidermal growth factor receptor 2). Oxygen plasma treatment of the carbon doped ZnOnFs gen-
erates functional groups (–COOH, –OH, etc.) that are eﬀective for the conjugation of anti-ErbB2. ZnOnFs
without plasma treatment that conjugate via electrostatic interactions were also tested for comparison.
Label-free detection of the breast cancer biomarker by this point-of-care device is achieved by an
electrochemical impedance technique that has high sensitivity (7.76 kΩ µM−1) and can detect 1 fM (4.34 ×
10−5 ng mL−1) concentration. The excellent impedimetric response of this immunosensor provides a fast
detection (128 s) in a wide detection test range (1.0 fM–0.5 μM). The oxy-plasma treated ZnOnF immuno-
electrode shows a higher association constant (404.8 kM−1 s−1) indicating a higher aﬃnity towards the
ErbB2 antigen compared to the untreated ZnOnF immunoelectrode (165.6 kM−1 s−1). This sensor is about
an order of magnitude more sensitive than the best demonstrated in the literature based on diﬀerent
nanomaterials and about three orders of magnitude better than the ELISA standard for breast cancer bio-
marker detection. This proposed point-of-care cancer diagnostic oﬀers several advantages, such as
higher stability, rapid monitoring, simplicity, cost-eﬀectiveness, etc., and should prove to be useful for the
detection of other bio- and cancer markers.
Introduction
With recent advances in genomics, proteomics and molecular
pathology, the detection of cancer biomarkers for the investi-
gation of genetic changes during malignant transformations is
found to be an interesting tool.1 Cancer biomarkers are the
chemical substances that are related to malignant tumors and
can be found in blood, urine, stool, other bodily fluids, or
tissues of aﬀected patients.2,3 Growth factor receptors, peptide
growth factors, signal transduction factors, tyrosine kinase
and transcription-regulatory proteins are over-expressed in
cancer cells. In particular, the human epidermal growth factor
receptor (EGFR or ErbB2) has been found in around 33% of
breast cancers.4,5 The ErbB2 gene is found on the 17q chromo-
some and encodes for the 185 kDa transmembrane tyrosine
kinase growth factor receptor.6 The discovery of ErbB2 gene
amplification, its overexpression in primary breast cancer and
most importantly its association with a more aggressive clini-
cal behavior makes ErbB2 a highly suitable candidate for diag-
nostics application.
The most widespread tools for breast cancer detection are
X-ray mammography and ultrasounds to investigate density
changes in the breast.7 Although the magnetic resonance
imaging technique is a highly sensitive tool, it lacks specificity.
Besides this, early diagnostics and costs are major concerns
for the quantification of cancerous molecules. Thus, biosensor
devices8 are considered to play an important role in the early
detection of breast cancer molecules since they oﬀer low costs,
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fast detection, portability, absence of side-eﬀects, etc. It is
known that the antigen and antibody of the epidermal growth
factor receptor in a cancer cell provides specific biding sites
(paratope and epitope) that allow the development of biosen-
sor devices to detect cancerous molecules.9 For example, anti-
body conjugated quantum dots have been utilized for the
detection of the HER2 biomarker in lung and breast cancer
cells,8 and Yong et al. fabricated bioconjugated indium phos-
phide (core)–zinc sulfide (shell) quantum dot nanoprobes for
the quantification of cancer molecules via imaging tech-
niques.10 Akter et al. developed an electrochemical immuno-
sensor based on multi walled carbon nanotubes and gold
nanocomposites for the amplified detection of a prostate
specific antigen.9
The application of nanostructured materials has grown
rapidly in biomedical fields including molecular imaging,
in vitro cancer cell studies, early diagnostics and personalized
treatments of cancer.11 One dimensional (1D) nanorods, nano-
wires and nanofibers of zinc oxide (ZnO) have been predicted
to have considerable potential for biomedical applications
including DNA delivery, bioimaging, magnetic resonance
imaging, nanoelectronics and biosensors devices due to their
higher surface-to-volume ratio, excellent electron transfer com-
munication, environmental safety, biocompatibility, non-
toxicity, chemical stability and biodegradability.12–16 The an-
isotropic structure of ZnO is known to exhibit higher electron
mobility and diﬀusion co-eﬃcient compared to other metal
oxides like titanium oxide.17 Nanofibers of ZnO due to their
high surface-to-volume and aspect ratios can play an important
role in electrochemical biosensors.13 Zinc oxide nanofibers
(ZnOnFs) may provide an electrical conduction path between
proteins and electrodes that enhance charge transfer pro-
perties resulting in a higher sensitivity of the biodevices. Thus,
there has been a rapid growth in the literature on the appli-
cation of nanopore metal oxides, including ZnO, for the detec-
tion of various biomolecules, such as glucose, DNA, antibodies
and bacteria, with improved stability and selectivity.18 The
nanopore structures result in an improved analytical perform-
ance due to the higher loading of active catalysts and higher
diﬀusion rates.19 Nanopore ZnO is found to be the most stable
because of its highly cross-linked structure that can resist bio-
degradation.20 Thus, the pore size, shape, hydrophilicity/
hydrophobicity, charge distribution, pH environment and con-
ductivity of ZnOnFs for biosensor applications can be tuned by
varying the composition of the material during its synthesis
process.
The bioconjugation of protein molecules with a metal oxide
surface has recently attracted much interest the development
of point-of-care (POC) diagnostics devices.21 Eﬀorts have been
made to identify the interaction of protein molecules with
the mesoporous metal oxides surface.22 Some of the important
factors associated with protein conjugation are the mesopore
structured diameter, surface-to-volume ratio, morphology,
surface modification, ionic strength, isoelectric point and
protein dimension. Surface chemistry on a metal oxide can
promote better conjugation of protein molecules by the cre-
ation of functional groups.23,24 Mesoporous 1D nanofibers are
known to facilitate the attachment of protein biomarkers (anti-
bodies) or DNA molecules due to their fascinating geometries
that can provide numerous absorption sites on the nanofiber
surface.25 For the conjugation of biomolecules, the physical
absorption driven by electrostatic attraction is a direct
approach for the attachment of biomolecules due to the
higher isoelectric point (10.3) of ZnOnF allowing it to easily
bind with the low isoelectric point protein molecules (∼1–5).20
Although non-specific binding due to electrostatic interactions
with foreign molecules may prove to be a disadvantage, this
method has been widely explored. However, covalent inter-
actions can overcome this limitation due to strong amide bond
formation. The zinc oxide surface can be modified by surface
treatments such as oxygen plasma, wet chemical, surface graft
polymerization, co-electrospinning, etc.14 Carbon doped in
ZnO not only helps to create surface functional groups but
also improves the electrochemical performance of a biosen-
sor.12,26 In addition, surface functional groups on the ZnOnF
surface in covalent interactions may amplify the electrochemi-
cal impedance signal. Xu et al. fabricated a 1D channel of
ordered mesoporous metal oxides to assemble functional pro-
teins for electrochemical detection of hydrogen peroxide.27
Mondal et al. fabricated mesoporous metal-oxide nanofibers
for the functionalization of cholesterol esterase and cholesterol
oxidase enzyme molecules.12 Hong et al. synthesized ZnO
nanowires for fluorescent cancer cell imaging.28 Ahmed et al.
fabricated a glucose biosensor using ZnOnF and obtained a
sensitivity (70.2 µA cm−2 mM−1) for glucose detection.13 Other
nanostructured materials including carbon nanotubes,29
reduced graphene oxide-SnO2 nanocomposite,
30 hydrazine
coated gold nanoparticles,30 etc., have been used to detect
cancer biomarkers. However, their limitations, such as poor
sensitivity and limit of detection, can be improved by using
porous morphology ZnOnFs. The mesoporous 1D ZnOnF has
not been explored for the fabrication of POC devices for cancer
biomarker detection to date.
Here we explore oxygen plasma treated and untreated
electrospun mesoporous zinc oxide nanofiber (ZnOnF) plat-
forms for conjugation with the antibody of human epidermal
growth factor receptor 2 (anti-ErbB2) and its use for the label-
free detection of ErbB2 via antigen–antibody interactions. Pre-
cursor materials such as a carrier polymer (polyacrylonitrile;
PAN) and zinc acetate were utilized for the synthesis of ZnOnF
mats via electrospinning followed by calcination. Shape, size
and diameter of the nanofibers was controlled by varying the
concentration of the precursor materials, solution viscosity,
flow rate, applied electric field, etc. A small amount of residual
carbon in the ZnOnFs was optimized for creating functional
groups to get the best sensor performance by varying the calci-
nation temperature. ZnOnFs deposited on indium tin oxide
glass are conjugated with anti-ErbB2 via covalent as well as
physical electrostatic interactions. Owing to the presence of
residual carbon in ZnOnFs, the oxygen plasma treatment gen-
erated functional groups such as –COOH, which make a strong
amide bond (C–N) with protein molecules. The functional
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property of ZnOnFs and their shape, size, crystalline structure,
etc., have been investigated using structural and morphological
studies. Label-free detection of ErbB2 has been carried out
using a protein conjugated ZnOnFs immunoelectrode via the
electrochemical impedance spectroscopic technique.
Results and discussion
Optimized synthesis and morphological studies of ZnOnFs
The synthesis of electrospun ZnO nanofibers was accom-
plished using a chemical method at a temperature of about
60 °C, including mixing of a metal acetate dihydrate salt, zinc
acetate dihydrate (ZnA) with a polar basic aprotic solvent
(DMF) followed by a high temperature (500 °C) thermal treat-
ment. The use of DMF as a useful reaction media for the
arrested basic hydrolysis of zinc salts has been reported
earlier.31 In this approach, DMF controls the hydrolysis of zinc
acetate dihydrate salts.32 The carrier polymer (PAN) dissolved
in DMF acts as a template and controls the growth kinetics of
ZnO. This precursor undergoes hydrolysis in the presence of
moisture and forms a ZnO gel in the electrospun nanofibers.
The as-spun nanofiber mats were left in air for stabilization to
permit the complete hydrolysis of ZnA. PAN was removed by
calcination leaving behind a continuous mesoporous ZnO
nanofiber mat with some residual carbon content.
The vital parameters for the electrospinning of PAN–ZnA
were optimized by Singh et al.33 to obtain uniform polymeric
fibers with diameters in the range of 180–350 nm. The role of
the sacrificial polymer PAN in the electrospun solution was to
increase the viscosity and therefore to control the viscoelastic
behavior of the blend. The diameter of the electrospun nano-
fibers could be varied, which is a determining factor in the
conductivity of the fibers and thereby increases biosensing
eﬃciency. The lower fiber diameter leads to a higher specific
surface area, therefore ensuring more reaction sites for enhan-
cing the electrocatalytic eﬃcacy. In order to optimize the dia-
meter of the fibers, we have fixed the applied voltage, distance
between the collector and the needle tip, ambient properties
like temperature and humidity while we varied the electro-
spinning process parameters like polymer wt% and flow rate
of the solution.
Electrospinning of ZnO occurs because of the high DC
potential applied between the needle tip and the grounded
rotating electrode. Because of the high voltage, the polymer
drop at the needle tip starts to elongate and a thin polymer jet
is ejected when the applied electric field strength beats the
surface tension of the polymer solution. Stretching of this
viscoelastic polymeric filament under the electric field coupled
with the rapid solvent evaporation produces nanofibers de-
posited on the grounded rotating electrode. A rotating drum
collector was used here to change the alignment of the col-
lected fibers. At low rpm (<500 rpm) the fibers were randomly
deposited onto the collector surface. As the rotational speed of
the drum was increased (usually >1000 rpm) fibers were col-
lected on the drum surface in a partially aligned orientation.
The diameter and morphology of the as-spun ZnOnFs were
confirmed by the field emission-scanning electron microscopy
(FE-SEM) studies. It was observed that at the solution flow rate
of 75 µL min−1 the diameter of the PAN–ZnA fibers decreases
with the reduction in polymer concentration. The fibrous mor-
phology is still retained up to a lower critical polymer concen-
tration ∼ 2 wt%. Below this concentration, electro-sprayed
bead like structures were formed. A combination of beads and
non-uniform fiber formation continues from 2 to 6 wt% as
revealed by the FE-SEM micrograph (Fig. 1a). The formation of
bead like structures occurs at low polymer wt% which inhibits
the Taylor cone formation. At low wt% of PAN (low viscoelasti-
city of polymer solution) the liquid jet breakdowns easily and
creates an electrospray of droplets/beads or beaded non-
uniform PAN–ZnA fibers. A further increase in PAN concen-
tration to 7.5 wt% produces a bead-free continuous fiber mat
of increasing diameter (Fig. 1b and c). At the very high
polymer concentration of 14 wt% thick rough non-uniform
diameter fibers (average diameter ∼0.85 µm) were obtained
(Fig. 1d). Therefore, the 7.5 wt% PAN solution was found to be
near optimal for producing bead-free, uniform diameter and
nanofiber mats with fiber diameter around 270 nm (calculated
from Fig. 1c).
When the flow rate of the PAN–ZnA solution (7.5 wt%) was
varied, the average fiber diameter was found to be ∼180 nm
and ∼650 nm for 15 µL min−1 and 150 µL min−1, respectively
(Fig. 1e and f). In order to preserve the Taylor cone, the flow
Fig. 1 FE-SEM micrographs for PAN–zinc acetate ﬁbers electrospun at
a 75 µL min−1 constant ﬂow rate with diﬀerent PAN concentrations, (a)
beaded and non-uniform PAN–ZnA ﬁbers observed at 3 wt%, (b) more
uniform in diameter bead-free ﬁbers at 7.5 wt%, (c) higher magniﬁcation
image of (b) and (d) thicker ﬁbers at 14 wt%. (e–f ) Morphology of a
7.5 wt% PAN–ZnA blend electrospun at diﬀerent ﬂow rates, (e) 15 µL
min−1 and (f ) 150 µL min−1.
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rate of the solution needs to be optimized accordingly.33 At
very low flow rates (15 µL min−1) dry polymer at the tip of the
needle was produced (Fig. 1e shows the beaded non uniform
fibers), whereas a very high flow (150 µL min−1) produced
large droplets and thick beaded fibers (Fig. 1f). Hence, it was
found that a 7.5 wt% PAN–ZnA solution at a flow rate of 75 µL
min−1 and a 14 kV DC voltage applied between the rotating
electrode and needle tip placed 4 cm apart, produced near
optimal thick nanofiber mats.
Structural and electron microscopic studies
Fig. 2 shows the morphology of the nanofibers after calcina-
tion at 500 °C. Fig. 2a shows the low magnification SEM image
of a free-standing ZnOnF mat (calcined at 500 °C) consisting
of partially aligned nanofibers. The as-spun nanofibers
(Fig. 1b and c) are of smooth morphology, free from beads,
uniform in diameter and are partially aligned in orientation.
Calcination at 500 °C (Fig. 2b and c) produced mesoporous
continuous long nanofibers with an average diameter of about
80 nm. Approximately a 70% shrinkage in the fiber diameter
was observed after calcination of the 7.5 wt% PAN–ZnA blend
electrospun at a 75 µL min−1 flow rate. As calcination was opti-
mized earlier,32 we calcined at 500 °C to retain a small amount
of residual carbon within the ZnOnF mats which may play an
important role in protein conjugation after oxy-plasma treat-
ment. Fig. 2d and e describe the morphology of the ZnOnFs
after the loading of antibodies (anti-ErbB2). It is confirmed
that ZnOnFs retain their fibrous morphology even after electro-
phoretic deposition (Fig. 2d and e). After immobilization via
surface treatment, the SEM image of the anti-ErbB2 covered
ZnOnF surface is shown in Fig. 2d. It can be seen that the
plasma treated fibers show less propensity for aggregation. In
addition, the mesopore structure of the ZnOnFs may enhance
the absorption of protein molecules. The high resolution
FE-SEM image after loading of the anti-ErbB2 molecules is
shown in Fig. 2e.
Elementary analysis for ZnOnF and fZnOnF films and with
antibody functionalization has been carried out to confirm the
presence of elements in the prepared samples. Fig. S1(i, ESI†)
shows the energy dispersive X-ray (EDX) analysis spectra
(embedded with the quantitative data) indicating removal of
the polymer with carbon present after calcination at 500 °C for
4 h (a). After antibody functionalization, an EDX peak appears
for the carbon element (atomic ratio; 12.2%) indicating the
presence of antibody molecules on the ZnOnF surface. Fig. S1
(ii, ESI†) shows the EDX analysis spectra (embedded with the
quantitative data) indicating removal of the polymer with
small amounts of residual carbon present after calcination.
After protein conjugation in the EDX spectra, elements such as
phosphorus (P), calcium (Ca), potassium (K) and chlorine (Cl)
found in the sample may be due to PBS with antibody on the
fZnOnF transducer surface (Fig. S1(ii), ESI†). However, the
atomic ratio of carbon elements is found to increase indicating
biofunctionalization of antibody on the fZnOnF transducer.
The microscopic structure of electrospun ZnOnFs obtained
after calcination was investigated by TEM studies. The dia-
meter of calcined ZnOnFs is around 60–120 nm after calcina-
tion at 500 °C. Fig. 2f shows the TEM images of ZnO fibers. It
is easy to identify ZnO grains from the magnified image
shown in the inset of Fig. 2f. This suggests that ZnOnFs crys-
tallized suﬃciently due to the high calcination temperature.
The average crystallite size of ZnO within the nanofibers is
found to be ∼32 nm by analyzing TEM micrographs (analyzed
by ImageJ software). The diameter of the fibers shrinks down
to about 80 nm by heat treatment. The grains of ZnO are pro-
duced from ZnA salt and grow by oxidation at high calcination
temperatures. The growth of the crystallites is along the fiber
direction. It can be seen that the ZnO nanofibers contain
small nanoparticles of ZnO along the fiber direction, however,
the inset shows nanostructured flower like ZnO wrapped along
the (101) direction of the ZnOnF, as confirmed by X-ray diﬀrac-
tion (XRD) studies.
The XRD studies were conducted to investigate the crystal-
line structure of synthesized ZnOnFs at a slow scan rate of 1°
min−1. The presence of various peaks in the XRD pattern
(Fig. 3i) indicates the wurtzite structure of crystalline zinc
oxide with the peaks matched to the JCPDS card no. 36-1451
(lattice parameters: a = 3.249 Å and c = 5.206 Å). The crystallite
size of zinc oxide (calcined at 500 °C) was calculated as
Fig. 2 FE-SEM images of ZnOnF produced at a calcination temperature
of 500 °C, (a) low magniﬁcation view of the calcined ZnO nanoﬁber
free-standing mat, (b) higher magniﬁcation view of the ZnO mat and (c)
individual high resolution image of ZnOnFs. (d) FE-SEM for ErbB2 anti-
body loading on ZnOnF surface and (e) its higher magniﬁcation. TEM
micrograph of ZnOnFs (f ), inset shows an individual ZnOnF.
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35.35 nm for the (101) plane using the Debye–Scherrer
equation. This indicates that the zinc oxide crystallites grow
along the (101) direction. A peak was found for the (002) reflec-
tion plane at 2θ = 22.6° due to the residual carbon content. In
the UV-visible spectra, it can be seen that absorption increases
from 420 nm to 250 nm and the maximum is at 350 nm due to
the quantum confinement eﬀect indicating the formation of
nanostructured zinc oxide (Fig. 3iii). The estimated band
gap (3.0 eV) of ZnOnFs is reduced compared to bulk zinc
oxide. Reduction of the band gap for the synthesized zinc
oxide nanofibers is due to the blue shift which may help
in enhancing electron conduction during electrochemical
measurements.
To investigate the porosity of synthesized ZnOnFs, we con-
ducted the Brunauer–Emmett–Teller (BET) measurement. For
sampling the specific surface area, the sample was degassed in
a vacuum at 200 °C for 8 h and then the nitrogen adsorption
and desorption isotherms were recorded (Fig. 3iv). The pore
size distribution was analyzed using non-local density func-
tional theory from the adsorption branch of the isotherm
(Fig. 3iv, inset). The volume was calculated from the adsorbed
nitrogen gas at a relative pressure (P/Po) of 0.9994. The total
BET surface area was found to be ∼28.07 m2 g−1 with an
average pore diameter of about 14.41 nm and all the pores
were below 326.9 nm in size. The pore volume was estimated
by the BJH desorption method as 10.11 × 10−2 cc g−1, where
the micro, meso and macropore volumes were distributed
around 0.0115, 0.057 and 0.03 cm3 g−1, respectively. Thus, the
results indicate that ZnOnFs consist of meso (57%) and macro-
pores (31.7%) with a fraction of around 11% micropores. The
mesoporous structure of zinc oxide fibers may enhance the
loading capacity of protein cancer biomarkers.
To confirm the available functional groups and formation
of chemical bonding on the ZnOnF surface, FT-IR studies were
performed (Fig. 3ii). In the finger print region of the spectra,
the peak seen at 533 cm−1 is due to the Zn–O vibration bend
in the sample. A wide absorption peak (curve a) was observed
at 3357 cm−1 corresponding to the Zn–OH stretching in the
ZnOnF sample. The strong absorption peak found at
1100 cm−1 reveals the presence of the O–C group on the
surface of ZnOnFs. The peak at 850 cm−1 indicates C–H
bending in the finger print region of the sample. The charac-
teristic peak at 1422 cm−1 is assigned to C–O–H bending while
at 1500 cm−1 is assigned to CvC bending. However, oxygen
plasma treatment of the ZnOnF surface changed the peak
position toward higher wavenumbers, from 1100 cm−1 to
1130 cm−1, and peak intensities were increased (curve b). A
peak observed at 1649 cm−1 reveals the presence of the carb-
oxyl group on fZnOnFs due to oxygen plasma treatment indi-
cating a –COOH functionalized surface (Mondal et al.).12 The
additional peak found at 2070 cm−1 is due to the absorption
of CO2 on the fZnOnF surface. After antibody (anti-ErbB2)
functionalization on the fZnOnF surface, the peaks as seen in
spectra c and d are found to disappear, indicating the absorp-
Fig. 3 (i) X-ray diﬀraction of synthesized zinc oxide nanoﬁbers calcined at 500 °C, inset shows the electron diﬀraction pattern of ZnOnFs, (ii) FT-IR
spectra of various fabricated electrodes, (iii) absorption spectra of ZnOnFs, (inset: Tauc plot for the band gap calculation), (iv) BET data for ZnOnFs
(inset: pore size distribution).
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tion of the antibody on the fZnOnF surface. A broad absorp-
tion peak found at 1040 cm−1 (curve d) due to C–N bending
arises from the covalent interaction of –COOH groups and
–NH2 groups of the fZnOnFs and anti-ErbB2, respectively. In
both spectra, a peak at 1631 cm−1, which is due to the N–H
stretching of the amide II bond, results after antibody ErbB2
absorption on ZnOnFs (c) and fZnOnFs (d).
Electrochemical properties
Cyclic voltammetric studies were conducted to investigate the
electrochemical properties for mesoporous ZnOnF based elec-
trodes in a wide potential range (−0.6 to 0.7 V). Curves show
excellent oxidation and reduction peaks for the fabricated elec-
trodes in the presence of the [Fe(CN)6]
3−/4− mediator (Fig. 4i).
The ZnOnF–ITO electrode shows an oxidation peak potential
of 0.37 V and current at 426 µA. Surface oxy-plasma treatment
on the ZnOnF surface results in a decreased oxidation current
due to the creation of functional groups (–COOH, –OH etc.).
The peak-to-peak separation voltage decreases to 0.32 V for the
fZnOnF–ITO electrode compared to the ZnOnF–ITO at 0.45
V. Anti-ErbB2 and BSA immobilization on the ZnOnF electrode
via electrostatic interactions obstructs [Fe(CN)6]
3−/4− diﬀusion
of electrons from the bulk solution resulting in a decreased
current (283 µA). Again, it is observed that the immobilization
of Anti-ErbB2 and BSA via covalent interactions followed by
oxygen plasma treatment (anti-ErbB2–fZnOnF–ITO) reduces
the electrochemical current compared to fZnOnF–ITO elec-
trode (266 µA). Conjugation of these protein molecules on the
ZnOnF surface perhaps acts as a barrier to electron transpor-
tation from the bulk solution towards the electrode resulting
in a decreased electrochemical current. Table S1† shows the
diﬀusion co-eﬃcients of various fabricated electrodes. It has
been observed that the higher diﬀusion co-eﬃcient (8.23 ×
10−8 cm2 s−1) of the porous morphology ZnOnF electrode may
be due to the high aspect ratio of mesoporous ZnOnFs that
provides an electron conduction path for transportation from
the bulk solution resulting in the higher diﬀusion of ions
towards the current collector. The diﬀusion of electrons due to
redox conversation for porous fZnOnF electrodes has been esti-
mated as 6.28 × 10−8 cm2 s−1. The functionalized ZnO nano-
fibers base electrode contains –COOH groups on its surface
that may obstruct electron diﬀusion from the bulk solution
compared to ZnOnFs without functionalization. However, anti-
body functionalization on ZnOnFs decreases the diﬀusion of
electrons (3.64 × 10−8 cm2 s−1) due to the attachment of insu-
lating antibody molecules on their surface. The antibody func-
tionalized electrode using fZnOnF again shows a decreased
diﬀusion of electrons (3.13 × 10−8 cm2 s−1), which may be due
to covalent interactions indicating that a higher amount of
antibody molecules can be attached to fZnOnFs. In scan rate
studies, we have measured the CV response of both fabricated
bioelectrodes (anti-ErbB2–fZnOnFs and anti-ErbB2–ZnOnFs)
Fig. 4 (i) Cyclic voltammetric studies for various electrodes and immunoelectrodes at 20 mV s−1, (ii) electrochemical impedance analysis for the
fabricated electrodes and (iii) equivalent circuit model for a typical Nyquist plot for impedance studies.
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as a function of scan rate (20–120 mV s−1) (Fig. S2, ESI†). The
peak-to-peak separation voltage of both bioelectrodes increases
and shifts toward the higher potential side with increasing
scan rates. The anodic and cathodic peak currents of both
bioelectrodes are found to be proportional and inversely pro-
portional with the square root of the scan rate. Thus, the
results of these studies indicate that both bioelectrodes show a
surface controlled process.34 The variation of the peak (anodic
and cathodic) current for both bioelectrodes as a function of
the square root of the scan rate follows eqn (1)–(4):
Ipa ðanti-ErbB2–ZnOnFsÞ ¼ 55 μ ½A2 mV1 s1=2
 Scan rate ½mV s11=2 þ 91 μA
ð1Þ
Ipc ðanti-ErbB2–ZnOnFsÞ ¼ 39 μ ½A2 mV1 s1=2
 Scan rate ½mV s11=2  151 μA
ð2Þ
Ipa ðanti-ErbB2–fZnOnFsÞ ¼ 43 μ ½A2 mV1 s1=2
 Scan rate ½mV s11=2 þ 83 μA
ð3Þ
Ipc ðanti-ErbB2–fZnOnFsÞ ¼ 27 μ ½A2 mV1 s1=2
 Scan rate ½mV s11=2  158 μA
ð4Þ
To investigate the interfacial property of the electrode–elec-
trolyte, we carried out electrochemical impedance spectro-
scopy (EIS) measurements as a function of frequency (0.01 −
105 Hz). The EIS spectra obtained for the fabricated electrodes
are shown in Fig. 4ii. The charge transfer resistance (Rct) and
constant phase element (CPE) of various electrodes has been
obtained from Nyquist plots (equivalent circuit diagram shown
in Fig. 4iii) using EIS measurements (Table S1†). The presence
of functional groups on the fZnOnF surface increases the Rct
value, however, the CPE value is decreased compared to the
fZnOnF electrode. This may be due to the enhanced hydro-
philic nature of ZnOnFs after surface oxygen plasma treat-
ment. Protein (antibody and BSA) conjugation on the ZnOnF
surface further enhances the Rct value. In addition, oxygen
plasma treatment of the ZnOnF electrode improves the loading
of protein molecules, which hinders the diﬀusion of electrons
produced in the oxidation/reduction of [Fe(CN)6]
3−/4− ions
resulting in a higher Rct (451 Ω) compared to the physical
absorption of protein molecules on the ZnOnF electrode
surface (Rct = 412 Ω). The reduction of the constant phase
element after protein immobilization indicates an attachment
of biomolecules on the ZnOnF surface resulting in an
increased electric double layer formed between the conductive
ITO electrode and an adjacent electrolyte. Interestingly, the
capacitive behavior of the ZnOnF electrode is changed by the
incorporation of functional groups on its surface for protein
conjugations. The low value of CPE for the anti-ErbB2–ZnOnF
immunoelectrode (2.31 × 10−5 F) indicates a higher double
layer distance compared to the anti-ErbB2–fZnOnF immunoe-
lectrode (2.72 × 10−5 F).
The heterogeneous electron transfer rate constant (k0) in
the presence of the [Fe(CN)6]
3−/4− mediator has been deter-
mined for various fabricated electrodes, as shown in
Table S1.† The value of k0 can be estimated using the relation
k0 = RT/n
2F2ARctC, where n is the electron transferring constant
of the redox couple, F is the Faraday constant, A is the area of
the electrode, R is the gas constant, T is the temperature, Rct is
the charge transfer resistance and C is the concentration of the
redox mediator. It is observed from Table S1† that the highest
electron transfer rate (11.1 × 10−7 cm s−1) occurs for the pris-
tine zinc oxide electrode, but declines for the oxy-plasma
treated and antibody functionalized electrodes with or without
plasma treatment. Surface treatment of the ZnOnF electrode at
the electrode–electrolyte interface could be responsible for the
observed dependence of the electron-transfer kinetics of the
[Fe(CN)6]
3−/4− mediator. A higher impedance or slower charge
transfer rate of the anti-ErbB2–fZnOnF immunoelectrode (47.3
× 10−7 cm s−1) results in the higher capacitance creation at the
electrode surface. The surface coverage (θ) can be calculated
using the relation θ = 1 − Rct (electrode)/Rct (bioelectrode),
where θ is the fraction of the occupied binding sites, and Rct
(electrode) and Rct (bioelectrode) are the surface specific
charge transfer resistances of the ZnOnF electrode and the
anti-ErbB2–ZnOnF bioelectrode, respectively. We have esti-
mated the surface concentration of physisorption and covalent
attachment of the antibody on the ZnOnF electrode surface as
53.6% and 54.1%, respectively. Thus a 0.5% enhancement of
surface coverage of covalently immobilized antibodies occurs
on the electrode surface via plasma treatment. The surface cov-
erage of the electrode can enhance the electrochemical sensi-
tivity and LOD of the biosensor device.
Electrochemical detection of the cancer biomarker
The electrochemical impedance spectroscopy (EIS) technique
was utilized for the label-free detection of human epidermal
growth factor receptor 2 (ErbB2). Anti-ErbB2 was functiona-
lized on the ZnOnF electrode surface with and without the
oxygen plasma treatment for the detection of various concen-
trations of ErbB2 (1.0 fM–0.5 µM). Fig. 5i and ii show the EIS
spectra of anti-ErbB2–ZnOnF and anti-ErbB2–fZnOnF electro-
des as a function of ErbB-2 concentration. These biosensors
can be regenerated by a glycine solution (0.2 M) at pH 2.4 for
two minutes which re-generated 96.5% of the initial signal. It
has been observed that the charge transfer resistance in these
EIS spectra increases with increasing concentration of ErbB-2.
Fig. 5iii and iv show the plots of the charge transfer resistances
(Rct) and logarithmic value of the ErbB-2 concentrations
for anti-ErbB2–ZnOnF and anti-ErbB2–fZnOnF immunoelec-
trodes. Interaction of specific binding sites of antigen and
antibody on the transducer surface form an immunocomplex
layer that obstructs the electron transfer from the bulk solu-
tion resulting in a higher Rct. It was found that the Rct value
for the anti-ErbB2–fZnOnF electrode is higher compared to the
anti-ErbB2–ZnOnF electrode (Fig. 5iii), which may be due to
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the available functional groups created after the oxygen
plasma treatment on the ZnOnF surface. These fabricated
immunoelectrodes can detect 1.0 fM concentration of ErbB2
within a range of concentration (1.0 fM–0.5 µM or 4.34 × 10−5–
2.17 × 104 ng mL−1). A comparable sensitivity for both anti-
ErbB2–fZnOnF (7.76 kΩ M−1 cm−2) and anti-ErbB2–ZnOnF
(7.6 kΩ M−1 cm−2) electrodes was obtained. The limit of detec-
tion (LOD) for anti-ErbB2–fZnOnF is low (1.3 M) compared to
the anti-ErbB2–ZnOnF (1.6 M) immunoelectrode. The three
dimensional structure of mesoporous ZnOnFs improves the
loading of protein molecules such as anti-ErbB2 and BSA
resulting in a higher sensitivity in both cases and an improved
stability of the immunosensor. Myung et al. developed a 3D
structure of a graphene based biosensor which significantly
increases the surface-to-volume ratio, thereby improving the
detection limits to 1.0 pM for HER2 and 100 pM for EGFR
breast cancer biomarkers.30 Tehrani et al. fabricated micro-
channels of a chemically modified multi-layer epitaxial gra-
phene based biosensor for the detection of a cancer biomarker
(8-hydroxydeoxyguanosine) that is sensitive up to 0.35 nM.35
However, the prepared biosensors can detect lower concen-
trations of ErbB2 compared to those of the reported biosensors
(Table 1),29,30,36,37 this may perhaps be because of the high
surface area of mesoporous ZnOnFs for antibody conjugation.
Table 1 shows the breast cancer sensing characteristics for the
fabricated immunoelectrodes alongwith those reported in lit-
erature. The control experiments for the ZnOnF and fZnOnF
electrodes were carried out with and without antibody (anti-
ErbB2) immobilization (Fig. S3, ESI†). The Rct values for the
electrodes are slightly changed in the presence of ErbB2 and
the values are not systematic. This may be due to the non-
specific binding with protein molecules in the presence of an
antigen solution. The detection time was found to be low (128
s) for the oxy-plasma treated immunoelectrode (fZnOnFs) com-
pared to the untreated ZnOnF immunoelectrode (141 s) as
shown in Fig. S4 (ESI†). Compared to the other reported bio-
sensors for breast cancer detection, the biosensor fabricated
here can detect a much lower concentration (1.0 fM) of the bio-
marker (Table 1). The association constant (Ka) for both the
fZnOnF and ZnOnF based immunoelectrodes is higher (404.8
kM−1 s−1 and 165.6 kM−1 s−1, respectively) compared to other
immunosensors reported.38,39 Thus the higher Ka of the
fZnOnF electrode indicates a high aﬃnity towards the ErbB2
antigen. This may perhaps be due to the covalent immobiliz-
ation of the antibody compared to the ZnOnF
immunoelectrode.
Reproducibility was investigated by detecting 100 nM of
ErbB2 with five diﬀerent immunoelectrodes under similar con-
ditions. The relative standard deviations (RSD) for the anti-
ErbB2–ZnOnF and anti-ErbB2–fZnOnF immunoelectrodes
were found to be 5.9% and 2.3%, respectively, which suggest
the good precision and reproducibility of the immunosensors.
The stability of the anti-ErbB2–ZnOnFs and anti-ErbB2–
fZnOnFs was investigated for 50 days. The anti-ErbB2–fZnOnF
immunosensor retained 95.5% of the initial signal value,
while an 88% signal retention was observed after 50 days in
the case of the anti-ErbB2–ZnOnF immunoelectrode (Fig. S5,
ESI†). To investigate the interference of the immunosensors,
Fig. 5 Impedance spectra for the (i) anti-ErbB2–ZnOnF and (ii) anti-ErbB2–fZnOnF immunoelectrodes as a function of ErbB2 concentration (1.0
fM–0.5 µM)]. Sensor calibration plots for the (iii) anti-ErbB2–ZnOnF and (iv) anti-ErbB2–fZnOnF immunoelectrodes using a logarithmic scale.
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the responses towards human IgG, cholesterol, PSA, glucose
and also with the BSA were determined considering their sig-
nificance in serum. The immunosensors were tested in the
presence of 100 nM of ErbB2 with normal concentrations of
interferents (Fig. S6, ESI†). The variation of charge transfer
resistance (Rct) due to the interfering substances was found to
be less than 5% for both immunoelectrodes, indicating good
selectivity.
Conclusions
We have demonstrated the fabrication of an eﬃcient, rapid
detection and highly sensitive label-free immunosensor using
antibody anchoring electrospun mesoporous zinc oxide nano-
fibers. The electrospun fibrous electrode was treated with
oxygen plasma to enhance the loading capacity of protein
(antibody) molecules via EDC–NHS covalent surface chemistry.
Electrochemical detection by the protein functionalized
fibrous immunoelectrode using the impedance spectroscopic
method was carried out with and without oxy-plasma treat-
ment on the ZnOnF surface for the concentration of the breast
cancer biomarker. In these prepared immunosensors the free-
standing mats of partially aligned ZnOnFs (diameters less
than 100 nm) were controlled during the synthesis of the
nanofibers, however, after the electrophoretic deposition of
the ZnOnFs onto the indium tin oxide surface their morpho-
logical order changed due to high the deposition potential.
The electrochemical property of the ZnOnF based electrode
changed with the protein molecules. The heterogeneous elec-
tron transfer constant and diﬀusion coeﬃcient of the antibody
conjugated ZnOnF electrode decreased, which influences the
impedance signal during ErbB2 detection. Thus, both fabri-
cated immunoelectrodes (oxy-plasma treated and untreated)
show a comparable analytical performance for the detection of
the breast cancer biomarker resulting in an insignificant
change in sensitivity and a significant change in the hetero-
geneous electron transfer rate constant, detection time and
association constant. These immunosensors provide a fast
response of 128 s and 141 s for the fZnOnF and ZnOnF bio-
electrodes, respectively, and are capable of detecting femto-
molar concentrations of ErbB2 in the wide range of 1 fM–0.5
µM without using any labeling agents with good sensitivity,
stability, reproducibility and selectivity. A mesoporous ZnOnF
based label-free immunosensor thus provides a suitable plat-
form for the early detection of breast cancer and may also find
applications in the eﬃcient detection of a host of other
biomarkers.
Materials and methods
Materials
N,N-Dimethyl-formamide (DMF) solvent was purchased from
Fischer Scientific, India. Zinc acetate (Zn (CH3COO)2, 2H2O,
99%), polyacrylonitrile (PAN (Mw = 1 50 000)), naphthalene and
anthracene were procured from Sigma-Aldrich, USA. Bovine
serum albumin (BSA), N-hydroxysuccinimide (NHS) and
N-ethyl-N′-(3-dimethylaminopropyl carbodiimide) (EDC) were
purchased from Sigma-Aldrich (USA). For stock solutions of
epidermal growth factor receptor, 2ErbB-2 (human recombi-
nant) we used 0.1 M acetate buﬀer at pH 4 (0.5 mg ml−1). To
dilute the stock solutions of ErbB2 we used acetate buﬀer (0.1
M). The polyclonal antibody of ErbB2 soluble in phosphate
buﬀered saline (PBS) containing 30% glycerol, 1% BSA and
0.02% thimerosal was purchased from BioVision, USA. Deio-
nized distilled water was from a Millipore water purification
system. The BSA (2 mg mL−1) solution was prepared in 50 mM
PBS (pH 7.4) containing 150 mM NaCl.
Instrumentation
The synthesized ZnOnFs were analysed by Fourier-transform
infra-red spectroscopy (FT-IR; Perkin-Elmer, Model 2000)
before and after oxygen plasma treatment. The morphological
shape and size of the ZnOnFs in diﬀerent conditions were
observed by Field emission scanning electron microscopy
(FE-SEM; Supra 400VP, Zeiss, Germany). Energy-dispersive
X-ray spectroscopy (EDX; Oxford Instruments) analyses for the
Table 1 Sensing performances of fabricated electrodes with the reported literature for the detection of breast cancer biomarker
Transducers Biomarkers Techniques Sensitivity
Detection
limit Test range
Association
constant (Ka) Reference
Reduced graphene
oxide-coated SiO2 NPs
HER2 FET-type — 1 pM 1 pM−1 μM — Myung et al.30
Opto-fluidic ring
resonator
HER2 Optical 30 nm/RIU sub-ng mL−1 13–100 ng mL−1 — Gohring et al.36
ZnO nanowires DNA based Electrochemical 6.36 µA µM−1 3.32 µM 10.0–100.0 µM — Mansor et al.37
Hydrazine-AuNP-
aptamer
HER2 Electrochemical 1.117 μA mL ng−1 0.037 pg mL−1 — — Zhu et al.40
Carbon nanotube Anti-breast
cancer agent
Electrochemical 8–925 nA µM−1 13.8 µM 40–160 μM — Baj-Rossi et al.29
ZnOnFs ErbB2 Impedance 7.6 kΩ µM−1 1.0 fM or 4.34 ×
10−5 ng mL−1
1 fM–0.5 μM
(4.34 × 10−5–
2.17 × 104
ng mL−1)
165.6 kM−1 s−1 Present work
fZnOnFs ErbB2 Impedance 7.76 kΩ µM−1 1.0 fM 1 fM–0.5 μM 404.8 kM−1 s−1 Present work
Paper Nanoscale
7242 | Nanoscale, 2015, 7, 7234–7245 This journal is © The Royal Society of Chemistry 2015
Pu
bl
ish
ed
 o
n 
17
 M
ar
ch
 2
01
5.
 D
ow
nl
oa
de
d 
by
 U
ni
ve
rs
ity
 o
f C
al
ga
ry
 o
n 
24
/0
5/
20
15
 1
9:
44
:5
8.
 
View Article Online
elemental composition of the ZnOnFs was carried out. The
X-ray diﬀraction (XRD; X’Pert Pro, PAN Analytical, Netherlands,
X-ray system with Cu Kα radiation and λ = 1.54 Å) pattern con-
firmed the crystalline structure of the synthesized ZnOnFs. UV-
visible analysis (Varian Cary 50Bio, UV-vis spectrophotometer)
was conducted to investigate the structural properties of
ZnOnFs. Brunauer–Emmett–Teller (BET; Quantachrome
Instruments, USA) was carried out to evaluate the pore size dis-
tribution and total surface area of ZnOnFs. Cyclic voltammetry
and electrochemical impedance spectroscopy were performed
using an Autolab Potentiostat/Galvanostat (Electrochemical
analyzer; AUT-84275) in PBS at pH 7.4 containing 5 mM of
[Fe(CN)6]
3−/4− as a mediator. Platinum (Pt) and Ag–AgCl elec-
trodes were used for counter and reference electrodes,
respectively.
Synthesis of mesoporous ZnOnFs
Synthesis of mesoporous ZnO nanofibers was demonstrated in
a previously reported paper.33 A pictorial representation is
shown in Scheme 1 with the synthesis protocol of zinc oxide
nanofibers. In brief, a 7.5 wt% PAN solution was prepared in
DMF solvent and magnetically stirred for 1 h at 60 °C. Then,
0.25 g of zinc acetate (ZnA) was mixed in the prepared PAN
solution and stirred for 6 h at 50 °C to obtain a homogenous
PAN–ZnA solution. This PAN–ZnA solution was transferred to a
plastic hypodermic syringe (Dispovan, Hindustan Syringes
Medical Devices Ltd, India) and fed through a syringe pump
(Harvard Apparatus, Holliston, MA) at a 75 µL min−1 flow rate.
An electric field (3.5 kV cm−1) was applied by a DC power
source (Gamma High Voltage, Inc., High Bridge, NJ) between
the needle tip and the rotating collector. The collector was
electrically grounded and rotated at 3000 rpm. This rotating
collection module consists of a rotating drum unit with a
translational linear motion emitter.
The non-woven fibers were collected for ∼5 h to make a
thick mat (0.1 mm) on a rotating drum electrode which was
covered with an aluminium foil. This free-standing mat like
structure of nanofibers was then heated in air at 165 °C for 3 h
to stabilize, which removes the solvent and moisture present
in the collected as-spun fibers. The above method was
repeated by varying parameters like the concentration of the
PAN solution and the solution flow rate at a constant electric
field. All the experiments were carried out in a controlled
atmosphere at a room temperature of 25 °C, 32% humidity
and at a pH value of 7. The nanofiber mats thus formed were
calcined at 500 °C (ramp rate = 5 °C min−1) for 2 h.
Electrode fabrication
In order to fabricate the electrode, 3.5 mg of an electrospun,
partially aligned ZnOnF free-standing mat were added to 5 ml
of acetonitrile and sonicated (40 W, 0.25 A) for 5 h. During
electrophoretic deposition, 1 mL of a ZnOnF suspended solu-
tion was added to 10 mL of an acetonitrile solution and soni-
cated. A platinum foil (1 cm × 2 cm) and a pre-cleaned ITO-
coated glass substrate (size; 0.5 cm2, sheet resistance; 30 Ω
cm−1) acted as the cathode and anode electrode, respectively.
These two electrodes were positioned parallel to each other
and separated by 1 cm and dipped in the ZnOnF colloidal sus-
pension. A DC voltage of 60 V was applied between the two
electrodes for 3 min in the presence of the ZnOnF colloidal
suspension. The suspended ZnOnFs were deposited uniformly
on the ITO electrode surface due to oppositely charged polarity
of the applied potential and ZnOnFs. Then, the deposited
films were removed from the ZnOnF suspension and washed
several times with de-ionised water followed by drying at
100 °C. Again, the ZnOnF electrode was treated with oxygen
plasma for covalent functionalization (fZnOnF) with the
antibody.
Device fabrication for breast cancer diagnostics
For antibody-ErbB2 functionalization, we explored both physi-
cal and covalent immobilizations. The anti-ErbB2–ZnOnF
(without plasma treatment) and anti-ErbB2–fZnOnF (with
plasma treatment) immunoelectrodes were used for the label-
free detection of epidermal growth factor receptor 2 (ErbB2;
breast cancer biomarker) via antigen–antibody interactions.
For physical immobilization the antibody-ErbB2 solution
(0.02 mg mL−1) was directly spread over the ZnOnF surface.
The physical adsorption of anti-ErbB2 has been carried out
without oxygen plasma treatment on the ZnOnF surface.
Prior to covalent functionalization, the ZnOnF based elec-
trodes were oxygen plasma treated and the vacuum pressure
was set to 0.005 mbar. The ZnOnF–ITO electrode with and
without surface treatment was utilized for conjugation of the
protein cancer biomarker (anti-ErbB2) via physical adsorption
as well as covalent attachment. During plasma treatment, oxi-
dation was performed in low intensity mode for 15 min, oxi-
dation voltage was kept at 450 V and pure oxygen was
supplied. In this process, various residual organic impurities
and weakly bound organic contaminations could be removed
from the ZnOnF–ITO surface. Thus, the plasma treatment
introduced various functional groups, such as –COOH, –OH,
etc., on ZnOnF–ITO and verified using FT-IR studies. The pre-
pared electrodes were treated with EDC–NHS for 4 h to activate
the functional groups (–COOH) on the ZnOnF electrode
surface. In EDC–NHS coupling chemistry, the EDC (0.2 M)
works as a coupling agent while NHS (0.05 M) works as an acti-
vator. This chemical treatment allowed for the binding of the
ZnOnFs and the antibody (anti-ErbB2) via a covalent amide
Scheme 1 Synthesis of electrospun ZnOnFs using a rotating drum
collector.
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bond on the fZnOnF (plasma treated) surface. An anti-ErbB2
solution (0.02 mg mL−1) was spread on the fZnOnF surface
and kept overnight under humid conditions (4 °C) followed by
washing with phosphate buﬀer containing 0.05% in order to
remove any unbound anti-ErbB2. The amide (C–N) bond for-
mation between the –COOH groups of the fZnOnFs–ITO and
the –NH2 groups of anti-ErbB2 result in improved immobiliz-
ation compared to the electrostatic interactions on the ZnOnF
surface. BSA (2 mg dL−1) was used for blocking the non-
specific adsorption of anti-ErbB2. The specific binding (para-
tope) of anti-ErbB2 on the transducer surface allows its inter-
action with antigen ErbB2 (epitope) resulting in a change of
electrochemical signal. For the electrochemical impedance
studies, the fabricated electrodes were immersed in a phos-
phate buﬀer saline (PBS) solution containing ferro/ferricyanide
mediator. Scheme 2 shows the fabrication of the immuno-
sensor and conjugation of the breast cancer biomarker with
the surface functionalization.
Acknowledgements
We are thankful to the Department of Science and Technology
(DST), New Delhi, India for their support to the Unit on Soft
Nanofabrication at the Indian Institute of Technology Kanpur.
Authors thank Dr Ved V. Agrawal for interesting discussions.
Notes and references
1 A. Mishra and M. Verma, Cancers, 2010, 2, 190–208.
2 G. Orphanos and P. Kountourakis, Hematology/Oncology
and Stem Cell Therapy, 2012, 5, 127–137.
3 D. Hanahan and R. A. Weinberg, Cell, 2011, 144, 646–674.
4 H. Zhang, A. Berezov, Q. Wang, G. Zhang, J. Drebin, R. Murali
and M. I. Greene, J. Clin. Invest., 2007, 117, 2051–2058.
5 A. Vasudev, A. Kaushik and S. Bhansali, Biosens. Bioelec-
tron., 2013, 39, 300–305.
6 D. Yu and M.-C. Hung, Breast cancer chemosensitivity,
Springer, New York, USA, 2007.
7 B. V. Chikkaveeraiah, A. A. Bhirde, N. Y. Morgan,
H. S. Eden and X. Chen, ACS Nano, 2012, 6, 6546–6561.
8 T. Y. Rakovich, O. K. Mahfoud, B. M. Mohamed, A. Prina-
Mello, K. Crosbie-Staunton, T. V. D. Broeck, L. D. Kimpe,
A. Sukhanova, D. Baty, A. Rakovich, S. A. Maier, F. Alves,
F. Nauwelaers, I. Nabiev, P. Chames and Y. Volkov, ACS
Nano, 2014, 8, 5682–5695.
9 R. Akter, M. A. Rahman and C. K. Rhee, Anal. Chem., 2012,
84, 6407–6415.
10 K.-T. Yong, H. Ding, I. Roy, W.-C. Law, E. J. Bergey,
A. Maitra and P. N. Prasad, ACS Nano, 2009, 3, 502–510.
11 J. Yao, M. Yang and Y. Duan, Chem. Rev., 2014, 114, 6130–
6178.
12 K. Mondal, M. A. Ali, V. V. Agrawal, B. D. Malhotra and
A. Sharma, ACS Appl. Mater. Interfaces, 2014, 6, 2516–2527.
13 M. Ahmad, C. Pan, Z. Luo and J. Zhu, J. Phys. Chem. C,
2010, 114, 9308–9313.
14 Y. Fang, Q. Pang, X. Wen, J. Wang and S. Yang, Small, 2006,
2, 612–615.
15 H. Hong, J. Shi, Y. Yang, Y. Zhang, J. W. Engle,
R. J. Nickles, X. Wang and W. Cai, Nano Lett., 2011, 11,
3744–3750.
16 P. K. Vabbina, A. Kaushik, N. Pokhrel, S. Bhansali and
N. Pala, Biosens. Bioelectron., 2015, 63, 124–130.
17 S. S. Mali, H. Kim, W. Y. Jang, H. S. Park and P. S. Patil,
ACS Sustainable Chem. Eng., 2013, 1, 1207–1213.
18 J. Liu, P. Pham, V. Haguet, F. Sauter-Starace, L. Leroy,
A. Roget, E. Descamps, A. Bouchet, A. Buhot, P. Mailley and
T. Livache, Anal. Chem., 2012, 84, 3254–3261.
Scheme 2 Immunosensor fabrication for a label-free detection of the breast cancer biomarker.
Paper Nanoscale
7244 | Nanoscale, 2015, 7, 7234–7245 This journal is © The Royal Society of Chemistry 2015
Pu
bl
ish
ed
 o
n 
17
 M
ar
ch
 2
01
5.
 D
ow
nl
oa
de
d 
by
 U
ni
ve
rs
ity
 o
f C
al
ga
ry
 o
n 
24
/0
5/
20
15
 1
9:
44
:5
8.
 
View Article Online
19 M. D. Scanlon, U. Salaj-Kosla, S. Belochapkine,
D. MacAodha, D. Leech, Y. Ding and E. Magner, Langmuir,
2012, 28, 2251–2261.
20 P. R. Solanki, A. Kaushik, V. V. Agrawal and B. D. Malhotra,
NPG Asia Mater., 2011, 3, 17–24.
21 P. Si, S. Ding, J. Yuan, X. W. D. Lou and D.-H. Kim, ACS
Nano, 2011, 5, 7617–7626.
22 C. E. Bunker, K. C. Novak, E. A. Guliants, B. A. Harruﬀ,
M. J. Meziani, Y. Lin and Y.-P. Sun, Langmuir, 2007, 23,
10342–10347.
23 H. S. Yoo, T. G. Kim and T. G. Park, Adv. Drug Delivery Rev.,
2009, 61, 1033–1042.
24 X. Ren, D. Chen, X. Meng, F. Tang, X. Hou, D. Han and
L. Zhang, J. Colloid Interface Sci., 2009, 334, 183–187.
25 R. S. Kane and A. D. Stroock, Biotechnol. Prog., 2007, 23,
316–319.
26 K. Mondal, S. Bhattacharyya and A. Sharma, Ind. Eng.
Chem. Res., 2014, 53, 18900–18909.
27 X. Xu, B. Z. Tian, J. L. Kong, S. Zhang, B. H. Liu and
D. Y. Zhao, Adv. Mater., 2003, 15, 1932–1936.
28 H. Hong, J. Shi, Y. Yang, Y. Zhang, J. W. Engle,
R. J. Nickles, X. Wang and W. Cai, Nano Lett., 2011, 11,
3744–3750.
29 C. Baj-Rossi, G. D. Micheli and S. Carrara, Sensors, 2012,
12, 6520–6537.
30 S. Myung, A. Solanki, C. Kim, J. Park, K. S. Kim and
K.-B. Lee, Adv. Mater., 2011, 23, 2221–2225.
31 G. Rodríguez-Gattorno, P. Santiago-Jacinto, L. Rendon-
Vázquez, J. Németh, I. Dekany and D. Diaz, J. Phys. Chem.
B, 2003, 107, 12597–12604.
32 M. E. Aguirre, H. B. Rodríguez, E. S. Roman, A. Feldhoﬀ
and M. A. Grela, J. Phys. Chem. C, 2011, 115, 24967–24974.
33 P. Singh, K. Mondal and A. Sharma, J. Colloid Interface Sci.,
2013, 394, 208–215.
34 S. Srivastava, M. A. Ali, P. R. Solanki, P. M. Chavhan,
M. K. Pandey, A. Mulchandani, A. Srivastava and
B. D. Malhotra, RSC Adv., 2013, 3, 228–235.
35 Z. Tehrani, G. Burwell, M. A. M. Azmi, A. Castaing,
R. Rickman, J. Almarashi, P. Dunstan, A. M. Beigi,
S. H. Doak and O. J. Guy, 2D Mater., 2014, 1, 025004.
36 J. T. Gohring, P. S. Dale and X. Fan, Sens. Actuators, B, 2010,
146, 226–230.
37 N. A. Mansor, Z. M. Zain, H. H. Hamzah, M. S. A. Noorden,
S. S. Jaapar, V. Beni and Z. H. Ibupoto, Open Journal of
Applied Biosensor, 2014, 3, 9–17.
38 M. A. Ali, S. Srivastava, M. K. Pandey, V. V. Agrawal,
R. John and B. D. Malhotra, Anal. Chem., 2014, 86,
1710–1718.
39 Z. Matharu, A. J. Bandodkar, G. Sumana, P. R. Solanki,
E. M. I. M. Ekanayake, K. Kaneto, V. Gupta and
B. D. Malhotra, J. Phys. Chem. B, 2009, 113, 14405–
14412.
40 Y. Zhu, P. Chandra and Y.-B. Shim, Anal. Chem., 2013, 85,
1058–1064.
Nanoscale Paper
This journal is © The Royal Society of Chemistry 2015 Nanoscale, 2015, 7, 7234–7245 | 7245
Pu
bl
ish
ed
 o
n 
17
 M
ar
ch
 2
01
5.
 D
ow
nl
oa
de
d 
by
 U
ni
ve
rs
ity
 o
f C
al
ga
ry
 o
n 
24
/0
5/
20
15
 1
9:
44
:5
8.
 
View Article Online
